EWM
LGND icon

Evercore Wealth Management’s Ligand Pharmaceuticals LGND Stock Holding History

Evercore Wealth Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-802
Closed -$26K – 912
2013
Q4 		$26K Sell
802
-54,341
-99% -$1.77M ﹤0.01% 648
2013
Q3 		$1.49M Sell
55,143
-3,286
-6% -$92.5K 0.09% 181
2013
Q2 		$1.36M Buy
+58,429
New +$1.05M 0.08% 184

Other funds holding LGND

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

Evercore Wealth Management's LGND Position: Q1 2014 in Review

Evercore Wealth Management sold out of Ligand Pharmaceuticals (LGND) in Q1 2014, closing a stake of 802 shares — an estimated $26K sold.

Evercore Wealth Management first reported a position in LGND in Q2 2013 and held it in 3 quarters. The position peaked at $1.49M in Q3 2013. 184 funds tracked by Wall St. Rank hold LGND as of Q1 2014.

  • Evercore Wealth Management reported no remaining Ligand Pharmaceuticals position as of Q1 2014 after selling out during the quarter.
  • Evercore Wealth Management sold 802 Ligand Pharmaceuticals shares in Q1 2014, an estimated $26K.
  • Evercore Wealth Management first reported a position in Ligand Pharmaceuticals in Q2 2013 and held it in 3 quarters.
  • Evercore Wealth Management's Ligand Pharmaceuticals position peaked at $1.49M in Q3 2013.
  • 184 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2014.

Based on Evercore Wealth Management's 13F filing for Q1 2014, filed 15 May 2014.